Who are Short treatment with benznidazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Short regimen of benznidazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/short-treatment-with-benznidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Short treatment with benznidazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short treatment with benznidazole (Short treatment with benznidazole) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antiparasitic. Area: Infectious Disease / Parasitology.

phase 3 Nitroimidazole antiparasitic Trypanosoma cruzi DNA and proteins Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Short treatment with benznidazole (Short treatment with benznidazole) — Laboratorio Elea Phoenix S.A.. Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Short treatment with benznidazole TARGET	Short treatment with benznidazole	Laboratorio Elea Phoenix S.A.	phase 3	Nitroimidazole antiparasitic	Trypanosoma cruzi DNA and proteins
Short regimen of benznidazole	Short regimen of benznidazole	Laboratorio Elea Phoenix S.A.	phase 3	Nitroimidazole antiparasitic	Trypanosoma cruzi DNA and cellular proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antiparasitic class)

Laboratorio Elea Phoenix S.A. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Short treatment with benznidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/short-treatment-with-benznidazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab